Cargando…

Colonization with multi-drug-resistant organisms negatively impacts survival in patients with non-small cell lung cancer

OBJECTIVES: Multidrug-resistant organisms (MDRO) are considered an emerging threat worldwide. Data covering the clinical impact of MDRO colonization in patients with solid malignancies, however, is widely missing. We sought to determine the impact of MDRO colonization in patients who have been diagn...

Descripción completa

Detalles Bibliográficos
Autores principales: Stratmann, Jan A., Lacko, Raphael, Ballo, Olivier, Shaid, Shabnam, Gleiber, Wolfgang, Vehreschild, Maria J. G. T., Wichelhaus, Thomas, Reinheimer, Claudia, Göttig, Stephan, Kempf, Volkhard A. J., Kleine, Peter, Stera, Susanne, Brandts, Christian, Sebastian, Martin, Koschade, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7688109/
https://www.ncbi.nlm.nih.gov/pubmed/33237921
http://dx.doi.org/10.1371/journal.pone.0242544
Descripción
Sumario:OBJECTIVES: Multidrug-resistant organisms (MDRO) are considered an emerging threat worldwide. Data covering the clinical impact of MDRO colonization in patients with solid malignancies, however, is widely missing. We sought to determine the impact of MDRO colonization in patients who have been diagnosed with Non-small cell lung cancer (NSCLC) who are at known high-risk for invasive infections. MATERIALS AND METHODS: Patients who were screened for MDRO colonization within a 90-day period after NSCLC diagnosis of all stages were included in this single-center retrospective study. RESULTS: Two hundred and ninety-five patients were included of whom 24 patients (8.1%) were screened positive for MDRO colonization (MDRO(pos)) at first diagnosis. Enterobacterales were by far the most frequent MDRO detected with a proportion of 79.2% (19/24). MDRO colonization was present across all disease stages and more present in patients with concomitant diabetes mellitus. Median overall survival was significantly inferior in the MDRO(pos) study group with a median OS of 7.8 months (95% CI, 0.0–19.9 months) compared to a median OS of 23.9 months (95% CI, 17.6–30.1 months) in the MDRO(neg) group in univariate (p = 0.036) and multivariate analysis (P = 0.02). Exploratory analyses suggest a higher rate of non-cancer-related-mortality in MDRO(pos) patients compared to MDRO(neg) patients (p = 0.002) with an increased rate of fatal infections in MDRO(pos) patients (p = 0.0002). CONCLUSIONS: MDRO colonization is an independent risk factor for inferior OS in patients diagnosed with NSCLC due to a higher rate of fatal infections. Empirical antibiotic treatment approaches should cover formerly detected MDR commensals in cases of (suspected) invasive infections.